These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 17933530)

  • 1. SAR studies of 1,5-diarylpyrazole-based CCK1 receptor antagonists.
    Gomez L; Hack MD; McClure K; Sehon C; Huang L; Morton M; Li L; Barrett TD; Shankley N; Breitenbucher JG
    Bioorg Med Chem Lett; 2007 Dec; 17(23):6493-8. PubMed ID: 17933530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pyrazole CCK(1) receptor antagonists. Part 1: Solution-phase library synthesis and determination of Free-Wilson additivity.
    McClure K; Hack M; Huang L; Sehon C; Morton M; Li L; Barrett TD; Shankley N; Breitenbucher JG
    Bioorg Med Chem Lett; 2006 Jan; 16(1):72-6. PubMed ID: 16236513
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pyrazole CCK(1) receptor antagonists. Part 2: SAR studies by solid-phase library synthesis and determination of Free-Wilson additivity.
    Sehon C; McClure K; Hack M; Morton M; Gomez L; Li L; Barrett TD; Shankley N; Breitenbucher JG
    Bioorg Med Chem Lett; 2006 Jan; 16(1):77-80. PubMed ID: 16236506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3-[5-(3,4-Dichloro-phenyl)-1-(4-methoxy-phenyl)-1H-pyrazol-3-yl]-2-m-tolyl-propionate (JNJ-17156516), a novel, potent, and selective cholecystokinin 1 receptor antagonist: in vitro and in vivo pharmacological comparison with dexloxiglumide.
    Morton MF; Barrett TD; Yan W; Freedman JM; Lagaud G; Prendergast CE; Moreno V; Pyati J; Figueroa K; Li L; Wu X; Rizzolio M; Breitenbucher JG; McClure K; Shankley NP
    J Pharmacol Exp Ther; 2007 Nov; 323(2):562-9. PubMed ID: 17684117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and evaluation of N-(3-oxo-2,3-dihydro-1H-pyrazol-4-yl)-1H-indole-carboxamides as cholecystokinin antagonists.
    Lattmann E; Singh H; Boonprakob Y; Lattmann P; Sattayasai J
    J Pharm Pharmacol; 2006 Mar; 58(3):393-401. PubMed ID: 16536908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel, achiral 1,3,4-benzotriazepine analogues of 1,4-benzodiazepine-based CCK(2) antagonists that display high selectivity over CCK(1) receptors.
    McDonald IM; Austin C; Buck IM; Dunstone DJ; Griffin E; Harper EA; Hull RA; Kalindjian SB; Linney ID; Low CM; Pether MJ; Spencer J; Wright PT; Adatia T; Bashall A
    J Med Chem; 2006 Apr; 49(7):2253-61. PubMed ID: 16570921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of 3-aryl-5-acylpiperazinyl-pyrazoles as antagonists to the NK3 receptor.
    Hoveyda HR; Roy MO; Blanc S; Noël S; Salvino JM; Ator MA; Fraser G
    Bioorg Med Chem Lett; 2011 Apr; 21(7):1991-6. PubMed ID: 21376585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and structure-activity relationships of a series of (1H-pyrazol-4-yl)acetamide antagonists of the P2X7 receptor.
    Chambers LJ; Stevens AJ; Moses AP; Michel AD; Walter DS; Davies DJ; Livermore DG; Fonfria E; Demont EH; Vimal M; Theobald PJ; Beswick PJ; Gleave RJ; Roman SA; Senger S
    Bioorg Med Chem Lett; 2010 May; 20(10):3161-4. PubMed ID: 20399651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anthranilic acid based CCK1 receptor antagonists: preliminary investigation on their second "touch point".
    Varnavas A; Lassiani L; Valenta V; Mennuni L; Makovec F; Hadjipavlou-Litina D
    Eur J Med Chem; 2005 Jun; 40(6):563-81. PubMed ID: 15922840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anthranilic acid based CCK1 antagonists: the 2-indole moiety may represent a "needle" according to the recent homonymous concept.
    Varnavas A; Lassiani L; Valenta V; Berti F; Tontini A; Mennuni L; Makovec F
    Eur J Med Chem; 2004 Jan; 39(1):85-97. PubMed ID: 14987837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anthranilic sulfonamide CCK1/CCK2 dual receptor antagonists I: discovery of CCKR1 selectivity in a previously CCKR2-selective lead series.
    Pippel M; Allison BD; Phuong VK; Li L; Morton MF; Prendergast C; Wu X; Shankley NP; Rabinowitz MH
    Bioorg Med Chem Lett; 2009 Nov; 19(22):6373-5. PubMed ID: 19811913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of concise, scalable route to a cholecystokinin 1 (CCK 1) receptor antagonist.
    Liang JT; Mani NS; Jones TK
    J Org Chem; 2007 Oct; 72(22):8243-50. PubMed ID: 17887796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-guided optimization of estrogen receptor binding affinity and antagonist potency of pyrazolopyrimidines with basic side chains.
    Zhou HB; Sheng S; Compton DR; Kim Y; Joachimiak A; Sharma S; Carlson KE; Katzenellenbogen BS; Nettles KW; Greene GL; Katzenellenbogen JA
    J Med Chem; 2007 Jan; 50(2):399-403. PubMed ID: 17228884
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and optimization of anthranilic sulfonamides as novel, selective cholecystokinin-2 receptor antagonists.
    Allison BD; Phuong VK; McAtee LC; Rosen M; Morton M; Prendergast C; Barrett T; Lagaud G; Freedman J; Li L; Wu X; Venkatesan H; Pippel M; Woods C; Rizzolio MC; Hack M; Hoey K; Deng X; King C; Shankley NP; Rabinowitz MH
    J Med Chem; 2006 Oct; 49(21):6371-90. PubMed ID: 17034143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and optimization of RO-85, a novel drug-like, potent, and selective P2X3 receptor antagonist.
    Brotherton-Pleiss CE; Dillon MP; Ford AP; Gever JR; Carter DS; Gleason SK; Lin CJ; Moore AG; Thompson AW; Villa M; Zhai Y
    Bioorg Med Chem Lett; 2010 Feb; 20(3):1031-6. PubMed ID: 20045645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemical and biological investigation of cyclopropyl containing diaryl-pyrazole-3-carboxamides as novel and potent cannabinoid type 1 receptor antagonists.
    Szabó G; Varga B; Páyer-Lengyel D; Szemzo A; Erdélyi P; Vukics K; Szikra J; Hegyi E; Vastag M; Kiss B; Laszy J; Gyertyán I; Fischer J
    J Med Chem; 2009 Jul; 52(14):4329-37. PubMed ID: 19527048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis of 7-benzyl-5-(piperidin-1-yl)-6,7,8,9-tetrahydro-3H-pyrazolo[3,4-c][2,7]naphthyridin-1-ylamine and its analogs as bombesin receptor subtype-3 agonists.
    Guo C; Guzzo PR; Hadden M; Sargent BJ; Yet L; Kan Y; Palyha O; Kelly TM; Guan X; Rosko K; Gagen K; Metzger JM; Dragovic J; Lyons K; Lin LS; Nargund RP
    Bioorg Med Chem Lett; 2010 May; 20(9):2785-9. PubMed ID: 20371178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biarylpyrazolyl oxadiazole as potent, selective, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity.
    Lee SH; Seo HJ; Lee SH; Jung ME; Park JH; Park HJ; Yoo J; Yun H; Na J; Kang SY; Song KS; Kim MA; Chang CH; Kim J; Lee J
    J Med Chem; 2008 Nov; 51(22):7216-33. PubMed ID: 18954042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antagonists of the calcium receptor I. Amino alcohol-based parathyroid hormone secretagogues.
    Marquis RW; Lago AM; Callahan JF; Trout RE; Gowen M; DelMar EG; Van Wagenen BC; Logan S; Shimizu S; Fox J; Nemeth EF; Yang Z; Roethke T; Smith BR; Ward KW; Lee J; Keenan RM; Bhatnagar P
    J Med Chem; 2009 Jul; 52(13):3982-93. PubMed ID: 19492813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1,3-Dipropyl-8-(1-phenylacetamide-1H-pyrazol-3-yl)-xanthine derivatives as highly potent and selective human A(2B) adenosine receptor antagonists.
    Tabrizi MA; Baraldi PG; Preti D; Romagnoli R; Saponaro G; Baraldi S; Moorman AR; Zaid AN; Varani K; Borea PA
    Bioorg Med Chem; 2008 Mar; 16(5):2419-30. PubMed ID: 18077171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.